Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/1/2002
1.
Phase I/II Study of Intracranial Iodine I 131 Labeled Anti-Tenascin Monoclonal Antibody 81C6 in Patients With Primary or Metastatic Malignant Anaplastic Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
3 and over
DUMC-2426-01-2R8
DUMC-000223-00-2R7, DUMC-0328-99-2R6, DUMC-221-96-2R3, DUMC-307-97-2R4, DUMC-307-98-2R5, NCI-H96-0009, NCT00002752
Last Modified:
7/1/2000
2.
Phase I/II Study of Intracystic Administration of 131I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 for Patients With Recurrent Cystic Gliomas (Summary Last Modified 07/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
3 and over
DUMC-1965-98-12R7
DUMC-1752-96-12R5, DUMC-1775-95-12R4, DUMC-1860-97-12R6, NCI-H96-0008, NCT00002753
Last Modified:
5/21/2007
 
First Published:
9/1/1998
3.
Phase I/II Randomized Study of Intratumoral Radiolabeled Antitenascin Monoclonal Antibody 81C6 in Patients With Newly Diagnosed or Recurrent Malignant Primary Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
DUMC-1529-01-8R4
DUMC-1363-97-9, DUMC-1409-98-9R1, DUMC-1529-00-8R3, DUMC-1630-99-9R2, DUMC-97112, NCI-5950NS20023, NCI-G98-1471, NCT00003478
Last Modified:
12/1/2002
 
First Published:
9/1/1998
4.
Phase I/II Study of Iodine I 131 Antitenascin Monoclonal Antibody 81C6 via Surgically Created Cystic Resection Cavity after Radiotherapy in Patients With Primary Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
DUMC-1533-02-8R5ER
DUMC-1533-01-8R4, DUMC-1373-97-9, DUMC-1408-98-9R1, DUMC-1533-00-8R3, DUMC-1570-99-9R2, DUMC-97107, NCI-5P0NS20023, NCI-G98-1472, NCT00003484
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute